Newly-diagnosed Pediatric T-cell ALL Protocol
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Status
- RECRUITING
- Phase
- PHASE3
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
- Status
- SUSPENDED
- Phase
- PHASE1
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE2
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE2
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
- Status
- RECRUITING
- Phase
- PHASE2
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
VHAG in Treating R/R T-ALL/LBL
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants
- Status
- COMPLETED
- Phase
- PHASE1
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
- Status
- RECRUITING
- Phase
- PHASE2
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2